Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm

Elias Jabbour, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview articlepeer-review

92 Scopus citations

Fingerprint

Dive into the research topics of 'Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm'. Together they form a unique fingerprint.

Medicine & Life Sciences